News&lnfo
RecBio is a high-tech enterprise jointly founded by the former vaccine R & D expert team from the Chinese Center for Disease Control and Prevention (China CDC) and the senior vaccine industrialization team.
The company has established a leading domestic R & D and innovation platform for new adjuvants, genetic engineering, and immune evaluation.

A Noah's Ark to combat COVID-19

  • Categories:News & Info
  • Author:Liu Yong
  • Origin:Taizhou Daily
  • Time of issue:2020-10-27
  • Views:0

(Summary description)The diagnostic reagents section of China Medical City has collectively risen to prominence in the fight against the COVID-19 pandemic, and made outstanding contributions.

A Noah's Ark to combat COVID-19

(Summary description)The diagnostic reagents section of China Medical City has collectively risen to prominence in the fight against the COVID-19 pandemic, and made outstanding contributions.

  • Categories:News & Info
  • Author:Liu Yong
  • Origin:Taizhou Daily
  • Time of issue:2020-10-27
  • Views:0
Information

The diagnostic reagents section of China Medical City has collectively risen to prominence in the fight against the COVID-19 pandemic, and made outstanding contributions. In terms of vaccine research and development, China Medical City, as the industrial cluster of vaccines, has not been absent or left behind, with at least three companies participating in the research and development of COVID-19 vaccines, each with its own unique technology route. I would like to provide an update on the vaccine development at RecBio from three aspects: progress, performance and capacity.

 

The first is the progress. We have adopted the technical route of protein subunit with new adjuvant, which takes 3-4 months to construct cell lines before we can get the protein for subsequent trials, so its progress is slower than other that of technical routes. The vaccine giants GSK and Sanofi have also adopted the same technical route and have roughly the same progress as ours. Thanks to the quick decision of China Medical City to offer us 18,000 square meters of the completed Phase VI standard facilities, Buildings 28 and 29, as the COVID-19 Vaccine Industrialization Base, thus saving us one year of construction time.

 

In terms of performance, we do not seek to be the fastest, but the best. As the main two factors that determine the performance of a vaccine are antigens and adjuvants, we have applied protein engineering technology to design dozens of antigens and different adjuvant combinations, conducted numerous animal experiments, and screened out the optimal formulation, with results that are even more promising than expected.

 

Capacity is another extremely critical factor. With the global spread of the COVID-19 pandemic, the establishment of an effective immune barrier requires the immunization of 70% of the population, and the global demand for vaccines is about 10 billion doses. Without sufficient capacity to cover enough people, any technology, however advanced it is, will be of limitedness in preventing the pandemic.

 

Our capacity is designed to be no less than 100 million doses per year, with room for a rapid doubling of production. More crucially, of all the technical routes, only recombinant protein vaccines can rapidly use the remaining capacity of the pharmaceutical industry. In the event of a pandemic crisis, our vaccine production capacity can cover the whole nation through cooperation with Taizhou pharmaceutical companies, and can cover the whole world through cooperation with provincial pharmaceutical companies. We hope that through vaccine research and development, we can work with our brother enterprises to hold up the Noah's Ark for mankind in the fight against the COVID-19 pandemic.

 

Finally, I would like to sum up my experience of the start-up in the China Medical City with three words, which are "caring, professional, and reassuring". Taizhou City provides great care for talent, not only giving them honor and favorable salaries, but more importantly, supporting their career development in an all-round way. RecBio is a scientist-led venture with few start-up capital and the Vaccine Engineering Center has provided RecBio with full plant and equipment support, as well as professional services. The clinical approvals for three kinds of vaccines of RecBio were successfully obtained thanks to the support of the New Drug Application Service Center. It is because of the attentive and professional services that talent can start their business in Taizhou with assurance. The first phase of RecBio's industrialization project focuses on the 9-valent HPV vaccine, with an investment of CNY 1 billion, and recently an additional investment of CNY 500 million is made in the COVID-19 vaccines; in the future, there will be more products launched in Taizhou.

 

Once bonded, it will last long. We will be permanently rooted in this entrepreneurial land of Taizhou!

Scan the QR code to read on your phone

  • TOP   

Contact Us

Jiangsu Rec-Biotechnology Co., Ltd.

tel:+86-523-86818860

 

Address: Vaccine Engineering Center, China Medical City, Taizhou

Copyright © 2020 Jiangsu Rec-Biotechnology Co., Ltd.  All rights reserved.      苏ICP备19043567号-1